Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024

血液腫瘍検査の世界市場予測(~2024年):アッセイキット、サービス

◆タイトル:Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024
◆商品コード:MD 7180
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年6月28日
◆ページ数:117
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥604,550見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥711,550見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥872,050見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、血液腫瘍検査の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品・サービス別(アッセイキット、サービス)分析、がん別(白血病(急性リンパ芽球性、急性骨髄性)、非ホジキンリンパ腫)分析、技術別(PCR、NGS、IHC)分析、エンドユーザー別(臨床検査室、病院)分析、血液腫瘍検査の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

“Hemato oncology testing market to register a CAGR of 14.8% from 2019 to 2024”The hemato oncology testing market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8% during the forecast period. Growth in this market is mainly driven by the rising incidences & prevalence of leukemia, increasing collaborations for developing new assay kits, and the growing focus on personalized medicine.

“Services accounted for the larger share of the hemato oncology testing market in 2018”
Based on product & service, the market is segmented into assay kits and services. In 2018, the services segment accounted for a larger share of this market majorly due to the high prevalence of leukemia & lymphoma. The market is set to grow on account of increasing collaborations between hemato oncology testing product manufacturers and pharmaceutical companies.

“Leukemia accounted for the largest share of the hemato oncology testing market in 2018”
Based on cancer type, the hemato oncology testing market has been segmented into three types— leukemia, lymphoma, and other cancers. Leukemia accounted for the largest share in 2018 and is anticipated to witness the highest growth rate during the forecast period due to the need for continuous monitoring of leukemia patients. In addition, increasing awareness about checking the status of minimal residual disease (MRD) in leukemia patients is another factor supporting market growth.

“North America dominates the hemato oncology testing market”
North America, which includes the US and Canada, accounted for the largest share of the hemato oncology testing in 2018. The large share of this market segment can be attributed to the availability of reimbursement for hemato oncology testing products, increasing awareness regarding advanced treatment theories, and the strong presence of industry players in the region.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1: 70% , Tier 2: 20%, and Tier 3: 10%
• By Designation: C-level: 30%, Director-level: 20%, and Others: 50%
• By Region: North America: 35%, Europe: 24%, Asia: 25%, and the RoW: 16%

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US).

Research Coverage
This report studies the hemato oncology testing market based on product & service, cancer type, technology, end user, and region. The report also analyzes factors (such as drivers, restraints, challenges, and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro-markets with respect to their growth trends, prospects, and contributions to the total hemato oncology testing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the hemato oncology testing offered by the top 12 players in the market. The report analyzes the hemato oncology testing market by product and region

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various hemato oncology testing across key geographic regions

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the hemato oncology testing market

• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the hemato oncology testing market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.2.1 MARKETS COVERED 14
1.2.2 YEARS CONSIDERED FOR THE STUDY 14
1.3 CURRENCY 15
1.4 LIMITATIONS 15
1.5 STAKEHOLDERS 15
2 RESEARCH METHODOLOGY 16
2.1 SECONDARY DATA 17
2.1.1 KEY DATA FROM SECONDARY SOURCES 17
2.2 PRIMARY DATA 18
2.2.1 KEY DATA FROM PRIMARY SOURCES 19
2.3 MARKET SIZE ESTIMATION 19
2.3.1 BOTTOM-UP APPROACH 20
2.3.2 TOP-DOWN APPROACH 20
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.5 ASSUMPTIONS FOR THE STUDY 22
3 EXECUTIVE SUMMARY 23
4 PREMIUM INSIGHTS 27
4.1 HEMATO-ONCOLOGY TESTING: MARKET OVERVIEW 27
4.2 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT AND SERVICE (2018) 28
4.3 GEOGRAPHICAL SNAPSHOT OF THE HEMATO-ONCOLOGY TESTING MARKET 29
5 MARKET OVERVIEW 30
5.1 INTRODUCTION 30
5.2 MARKET DYNAMICS 30
5.2.1 DRIVERS 31
5.2.1.1 Increasing incidence of hematologic cancer 31
5.2.1.2 Increasing collaborations 32
5.2.1.3 Increasing conferences on personalized medicine 32
5.2.2 OPPORTUNITIES 33
5.2.2.1 Drug diagnostics co-development 33
5.2.2.2 Emerging markets 33
5.2.3 RESTRAINTS 34
5.2.3.1 Uncertain reimbursement scenario in different regions 34
5.2.3.2 Complex regulatory frameworks delaying the approval of new molecular diagnostic tests 35
5.2.4 CHALLENGES 36
5.2.4.1 Intellectual property rights protection issues 36
6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE 37
6.1 INTRODUCTION 38
6.2 SERVICES 39
6.2.1 RISING INCIDENCE OF HEMATOLOGIC CANCER TO INCREASE THE DEMAND FOR HEMATO-ONCOLOGY SERVICES 39
6.3 ASSAY KITS 40
6.3.1 GROWING FOCUS ON THE DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 40
7 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 42
7.1 INTRODUCTION 43
7.2 LEUKEMIA 44
7.2.1 ACUTE MYELOID LEUKEMIA 45
7.2.1.1 AML IS THE MOST COMMON ACUTE LEUKEMIA AFFECTING ADULTS 45
7.2.2 ACUTE LYMPHOCYTIC LEUKEMIA 45
7.2.2.1 North America accounted for the largest share of the ALL segment 45
7.2.3 OTHER LEUKEMIAS 46
7.3 LYMPHOMA 47
7.3.1 NON-HODGKIN LYMPHOMA 48
7.3.1.1 Non-Hodgkin lymphoma holds the largest share of the market for lymphoma 48
7.3.2 HODGKIN LYMPHOMA 48
7.3.2.1 APAC hemato-oncology testing market for Hodgkin lymphoma will grow at the highest rate 48
7.4 OTHER CANCERS 49
8 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 50
8.1 INTRODUCTION 51
8.2 PCR 52
8.2.1 PCR ACCOUNTED FOR THE LARGEST SHARE OF THE HEMATO-ONCOLOGY TESTING MARKET IN 2018 52
8.3 IHC 53
8.3.1 IHC ACCOUNTED FOR THE SECOND-LARGEST SHARE OF THE HEMATO-ONCOLOGY TESTING MARKET 53
8.4 NGS 53
8.4.1 NGS IS EXPECTED TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 53

8.5 CYTOGENETICS 54
8.5.1 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE CYTOGENETICS MARKET 54
8.6 OTHER TECHNOLOGIES 55
9 HEMATO-ONCOLOGY TESTING MARKET, BY END USER 56
9.1 INTRODUCTION 57
9.2 CLINICAL LABORATORIES 58
9.2.1 PRESENCE OF ROBUST INFRASTRUCTURE IS THE MAJOR DRIVING FACTOR FOR THIS SEGMENT 58
9.3 HOSPITALS 59
9.3.1 HOSPITALS ACCOUNTED FOR THE SECOND-LARGEST SHARE OF THE MARKET, BY END USER 59
9.4 ACADEMIC & RESEARCH INSTITUTES 60
9.4.1 APAC MARKET FOR ACADEMIC & RESEARCH INSTITUTES WILL GROW AT THE HIGHEST RATE 60
9.5 OTHER END USERS 60
10 HEMATO-ONCOLOGY TESTING MARKET, BY REGION 62
10.1 INTRODUCTION 63
10.2 NORTH AMERICA 64
10.2.1 US 68
10.2.1.1 The US dominates the North American hemato-oncology testing market 68
10.2.2 CANADA 71
10.2.2.1 Initiatives undertaken by healthcare authorities in the country to ensure the delivery of better public healthcare to support the growth of the hemato-oncology testing market in Canada 71
10.3 EUROPE 74
10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET GROWTH 74
10.4 ASIA PACIFIC 77
10.4.1 ASIA PACIFIC MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 77
10.5 REST OF THE WORLD 81
11 COMPETITIVE LANDSCAPE 84
11.1 OVERVIEW 84
11.2 MARKET RANKING ANALYSIS, 2017 85
11.3 KEY STRATEGIES 86
11.3.1 PRODUCT LAUNCHES & APPROVALS, 2016–2019 86
11.3.2 EXPANSIONS, 2016–2019 86
11.3.3 PARTNERSHIPS AND COLLABORATIONS, 2016–2019 86
11.3.4 ACQUISITIONS, 2016–2019 87
12 COMPANY PROFILES 88
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 F. HOFFMAN-LA ROCHE LTD. 88
12.2 ABBOTT LABORATORIES 90
12.3 QIAGEN N.V. 92
12.4 THERMO FISHER SCIENTIFIC, INC. 94
12.5 ILLUMINA, INC. 96
12.6 BIO-RAD LABORATORIES, INC. 98
12.7 MOLECULARMD (SUBSIDIARY OF ICON PLC) 100
12.8 ARCHERDX, INC. 102
12.9 ARUP LABORATORIES INC. 103
12.10 ASURAGEN, INC. 104
12.11 INVIVOSCRIBE, INC. 105
12.12 ADAPTIVE BIOTECHNOLOGIES. 107
*Details on Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 109
13.1 INSIGHTS OF INDUSTRY EXPERTS 109
13.2 DISCUSSION GUIDE 110
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 113
13.4 AVAILABLE CUSTOMIZATIONS 115
13.5 RELATED REPORTS 115
13.6 AUTHOR DETAILS 116

LIST OF TABLES

TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2018–2040 31
TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030 31
TABLE 3 HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2009 VS. 2016 33
TABLE 4 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030 34
TABLE 5 REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS 34
TABLE 6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION) 38
TABLE 7 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION,
2017–2024 (USD MILLION) 39
TABLE 8 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 40
TABLE 9 HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION,
2017–2024 (USD MILLION) 41
TABLE 10 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 43
TABLE 11 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION,
2017–2024 (USD MILLION) 44
TABLE 12 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE,
2017–2024 (USD MILLION) 44
TABLE 13 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA,
BY REGION, 2017–2024 (USD MILLION) 45
TABLE 14 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA,
BY REGION, 2017–2024 (USD MILLION) 46
TABLE 15 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2017–2024 (USD MILLION) 46
TABLE 16 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION,
2017–2024 (USD MILLION) 47
TABLE 17 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE,
2017–2024 (USD MILLION) 47
TABLE 18 HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA,
BY REGION, 2017–2024 (USD MILLION) 48
TABLE 19 HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA,
BY REGION, 2017–2024 (USD MILLION) 49
TABLE 20 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION,
2017–2024 (USD MILLION) 49
TABLE 21 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 51
TABLE 22 HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION,
2017–2024 (USD MILLION) 52
TABLE 23 HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION,
2017–2024 (USD MILLION) 53
TABLE 24 HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION,
2017–2024 (USD MILLION) 54
TABLE 25 HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION,
2017–2024 (USD MILLION) 55
TABLE 26 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2017–2024 (USD MILLION) 55
TABLE 27 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017–2024 (USD MILLION) 57
TABLE 28 HEMATO-ONCOLOGY TESTING MARKET FOR REFERENCE LABORATORIES,
BY REGION, 2017–2024 (USD MILLION) 58
TABLE 29 HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION,
2017–2024 (USD MILLION) 59
TABLE 30 HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2017–2024 (USD MILLION) 60
TABLE 31 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2017–2024 (USD MILLION) 61
TABLE 32 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2017–2024 (USD MILLION) 63
TABLE 33 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY,
2017–2024 (USD MILLION) 65
TABLE 34 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION) 65
TABLE 35 NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 65
TABLE 36 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION) 66
TABLE 37 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA,
BY TYPE, 2017–2024 (USD MILLION) 66
TABLE 38 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA,
BY TYPE, 2017–2024 (USD MILLION) 66
TABLE 39 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 67
TABLE 40 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER,
2017–2024 (USD MILLION) 67
TABLE 41 US: LEUKEMIA AT A GLANCE 68
TABLE 42 US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION) 69
TABLE 43 US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 69
TABLE 44 US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE,
2017–2024 (USD MILLION) 69
TABLE 45 US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE,
2017–2024 (USD MILLION) 70
TABLE 46 US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 70
TABLE 47 US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER,
2017–2024 (USD MILLION) 70
TABLE 48 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION) 71
TABLE 49 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 72
TABLE 50 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE,
2017–2024 (USD MILLION) 72
TABLE 51 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA,
BY TYPE, 2017–2024 (USD MILLION) 72
TABLE 52 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 73
TABLE 53 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER,
2017–2024 (USD MILLION) 73
TABLE 54 INCIDENCE OF LEUKEMIA, BY COUNTRY, 2018–2035 74
TABLE 55 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION) 74
TABLE 56 EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 75
TABLE 57 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 75
TABLE 58 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE,
2017–2024 (USD MILLION) 75
TABLE 59 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION) 76
TABLE 60 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 76
TABLE 61 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER,
2017–2024 (USD MILLION) 77
TABLE 62 GERIATRIC POPULATION, BY COUNTRY, 2015 VS. 2030 77
TABLE 63 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION) 78
TABLE 64 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 78
TABLE 65 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 79
TABLE 66 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017–2024 (USD MILLION) 79
TABLE 67 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION) 79
TABLE 68 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 80
TABLE 69 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER,
2017–2024 (USD MILLION) 80
TABLE 70 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE,
2017–2024 (USD MILLION) 81
TABLE 71 ROW: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE,
2017–2024 (USD MILLION) 81
TABLE 72 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION) 82
TABLE 73 ROW: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE,
2017–2024 (USD MILLION) 82
TABLE 74 ROW: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE,
2017–2024 (USD MILLION) 82
TABLE 75 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION) 83
TABLE 76 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY END USER,
2017–2024 (USD MILLION) 83
TABLE 77 RANKING OF COMPANIES IN THE HEMATO-ONCOLOGY TESTING MARKET, 2018 85


LIST OF FIGURES

FIGURE 1 HEMATO-ONCOLOGY TESTING MARKET 14
FIGURE 2 RESEARCH DESIGN 16
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 18
FIGURE 4 HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH 20
FIGURE 5 HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH 20
FIGURE 6 DATA TRIANGULATION METHODOLOGY 21
FIGURE 7 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT AND SERVICE,
2019 VS. 2024 (USD MILLION) 23
FIGURE 8 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE,
2019 VS. 2024 (USD MILLION) 24
FIGURE 9 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY,
2019 VS. 2024 (USD MILLION) 24
FIGURE 10 HEMATO-ONCOLOGY TESTING MARKET, BY END USER,
2019 VS. 2024 (USD MILLION) 25
FIGURE 11 HEMATO-ONCOLOGY TESTING MARKET, BY REGION,
2019 VS. 2024 (USD MILLION) 25
FIGURE 12 INCREASING INCIDENCE OF HEMATOLOGY CANCER TO DRIVE MARKET GROWTH 27
FIGURE 13 SERVICES TO DOMINATE THE NORTH AMERICAN MARKET IN 2018 28
FIGURE 14 NORTH AMERICA ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2018 29
FIGURE 15 HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
& CHALLENGES 30
FIGURE 16 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2019 VS. 2024) 38
FIGURE 17 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE (2019 VS. 2024) 43
FIGURE 18 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY (2019 VS. 2024) 51
FIGURE 19 HEMATO-ONCOLOGY TESTING MARKET, BY END USER (2019 VS. 2024) 57
FIGURE 20 HEMATO-ONCOLOGY TESTING MARKET, BY REGION (2019 VS. 2024) 63
FIGURE 21 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT 64
FIGURE 22 KEY DEVELOPMENTS IN THE HEMATO-ONCOLOGY TESTING MARKET FROM
2016 TO 2018 84
FIGURE 23 ROCHE DIAGNOSTIC: COMPANY SNAPSHOT (2018) 88
FIGURE 24 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2018) 90
FIGURE 25 QIAGEN N.V.: COMPANY SNAPSHOT (2018) 92
FIGURE 26 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018) 94
FIGURE 27 ILLUMINA, INC.: COMPANY SNAPSHOT (2018) 96
FIGURE 28 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2018) 98
FIGURE 29 ICON PLC: COMPANY SNAPSHOT (2018) 100


★調査レポート[血液腫瘍検査の世界市場予測(~2024年):アッセイキット、サービス] ( Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024 / MD 7180) 販売に関する免責事項
[血液腫瘍検査の世界市場予測(~2024年):アッセイキット、サービス] ( Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) - Global Forecast to 2024 / MD 7180) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆